Co-founder, President and Chief Executive Officer
United States of America
David is the Co-founder, President and Chief Executive Officer of Frequency Therapeutics. He has over 20 years of entrepreneurial experience and has played an integral role in launching, building and operating many successful companies in the life sciences and other innovation sectors. Previously, David was the President and Chief Executive Officer of Entrega Bio, a PureTech Health (UK:PRTC) company developing an innovative capsule technology to make injectable substances available orally. David’s first MIT-based startup was Semprus BioSciences, a biomedical company that went from business concept, to FDA 510(k) clearance and CE Mark approval, to major acquisition in five years. Semprus won the MIT $100K Entrepreneurial Competition for its business plan to develop a novel platform technology for reducing complications associated with long-term medical device implants, such as thrombosis and microbial adhesion. David subsequently led Semprus’ closing on several large financings before the company was acquired by Teleflex in 2012. Prior to Semprus, David was a Senior Executive at the leading venture capital firm, Polaris Partners, where he was responsible for deal-sourcing and originating and the execution of Polaris’ investment in Athletes Performance, a leading training facility for NFL, MLB, NHL and NBA professional athletes.